665 related articles for article (PubMed ID: 34344638)
1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Cavo M; Dimopoulos MA; San-Miguel J; Mateos MV; Jakubowiak A; Deraedt W; Lam A; Kampfenkel T; Qi M; He J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):480-489. PubMed ID: 32278674
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
[TBL] [Abstract][Full Text] [Related]
4. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
Fujisaki T; Ishikawa T; Takamatsu H; Suzuki K; Min CK; Lee JH; Wang J; Carson R; Crist W; Qi M; Nagafuji K
Ann Hematol; 2019 Dec; 98(12):2805-2814. PubMed ID: 31620815
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W; Bang SM; Huang H; Kim K; Li W; An G; Lee JJ; Cai Z; Jin J; Wang Y; Lin TL; Chim CS; Qi M; Wang J; Lu X; Song Y; Jia B; Yang X; Liu W; Zhou T; Yin L; Li Y; Zhang R; Hou J; Wang J
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):446-455.e4. PubMed ID: 37024420
[TBL] [Abstract][Full Text] [Related]
7. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Lee JH; Moreau P; Niesvizky R; Dimopoulos M; Hajek R; Pour L; Jurczyszyn A; Qiu L; Klippel Z; Zahlten-Kumeli A; Osman M; Paiva B; San-Miguel J
Blood; 2019 May; 133(18):1953-1963. PubMed ID: 30819926
[TBL] [Abstract][Full Text] [Related]
9. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Syed YY
Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
[TBL] [Abstract][Full Text] [Related]
13. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.
Li S; Li J; Peng L; Tan C; Zeng X; Peng C; Zhang C; Li Y; Wan X
Clin Ther; 2021 Jul; 43(7):1253-1264.e5. PubMed ID: 34193346
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
[TBL] [Abstract][Full Text] [Related]
15. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Leukemia; 2022 Apr; 36(4):1066-1077. PubMed ID: 34974527
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
19. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Mateos MV; San-Miguel J; Goldschmidt H; Sonneveld P; Dimopoulos MA; Heeg B; Hashim M; Deraedt W; Hu P; Lam A; He J
Leuk Lymphoma; 2020 Mar; 61(3):680-690. PubMed ID: 31686561
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
